Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Evaluation report:

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Astellas

03. Consultee comments on the ACD - Prostate Cancer UK

04. Consultee comments on the ACD - Tackle Prostate Cancer

05. Consultee comments on the ACD - British Uro-Oncology Group

06. Consultee comments on the ACD - Royal College of Nursing

07. Consultee comments on the ACD - Royal College of Physicians

08. Commentator comments on the ACD - Janssen

09. Comments on the Appraisal Consultation Document received through the NICE website, from members of the public and from Members of Parliament

10. Evidence Review Group critique of additional information submitted by the Manufacturer, Astellas

This page was last updated: 06 May 2014